BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tibsovo (Ivosidenib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tibsovo (Ivosidenib)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02074839-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tibsovo (Ivosidenib): Phase 1 readout est. (NCT02074839)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 1\, Acute Myeloid Leukemia.\nStudy
 : Study of Orally Administered AG-120 in Subjects With Advanced Hematologi
 c Malignancies With an IDH1 Mutation\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivosideni
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02
 074839
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05010772-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tibsovo (Ivosidenib): Phase 1 readout est. (NCT05010772)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 1\, Acute Myeloid Leukemia.\nStudy
 : Decitabine Alone or in Combination With Venetoclax\, Gilteritinib\, Enas
 idenib\, or Ivosidenib as Maintenance Therapy for the Treatment of Acute M
 yeloid Leukemia in Remission\nEstimated primary completion: 31 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ivosidenib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05010772
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04278781-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT04278781)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2.\nStudy: AG-120 in People With I
 DH1 Mutant Chondrosarcoma\nEstimated primary completion: March 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ivosidenib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04278781
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03503409-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270402
DTEND;VALUE=DATE:20270403
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT03503409)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Sy
 ndrome\nEstimated primary completion: 2 April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03503409
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03839771-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270417
DTEND;VALUE=DATE:20270418
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT03839771)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3\, Acute Myeloid Leukemia.\nStudy
 : A Study of Ivosidenib or Enasidenib in Combination With Induction Therap
 y and Consolidation Therapy\, Followed by Maintenance Therapy in Patients 
 With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2\
 , With an IDH1 or IDH2 Mutation\, Respectively\, Eligible for Intensive Ch
 emotherapy\nEstimated primary completion: 17 April 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03839771
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05756777-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270421
DTEND;VALUE=DATE:20270422
SUMMARY:Tibsovo (Ivosidenib): Phase 1 readout est. (NCT05756777)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 1\, Acute Myeloid Leukemia.\nStudy
 : A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in 
 People With Acute Myeloid Leukemia (AML)\nEstimated primary completion: 21
  April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivosiden
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5756777
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07607418-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT07607418)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated 
 AML and HR-MDS\nEstimated primary completion: 30 May 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07607418
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548710-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT07548710)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Study of SA+X in the Treatment of Newly Diagnosed AML\nEstimated primary
  completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ivosidenib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07548710
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615818-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT05615818)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3.\nStudy: Personalized Medicine f
 or Advanced Biliary Cancer Patients\nEstimated primary completion: June 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ivosidenib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05615818
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06501625-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Tibsovo (Ivosidenib): Phase 1/2 readout est. (NCT06501625)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 1/2.\nStudy: Ivosidenib Plus Durva
 lumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With
  Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation\n
 Estimated primary completion: 13 September 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06501625
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03471260-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tibsovo (Ivosidenib): Phase 1/2 readout est. (NCT03471260)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 1/2\, Acute Myeloid Leukemia.\nStu
 dy: Ivosidenib and Venetoclax With or Without Azacitidine in Treating Pati
 ents With IDH1 Mutated Hematologic Malignancies\nEstimated primary complet
 ion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ivosidenib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03471260
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05401097-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT05401097)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in th
 e Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for
  Intensive Induction Therapy (I- DATA Study)\nEstimated primary completion
 : 30 September 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ivosidenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05401097
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05907057-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT05907057)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3\, Acute Myeloid Leukemia.\nStudy
 : An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidi
 ne in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AM
 L) Ineligible for Intensive Induction Chemotherapy.\nEstimated primary com
 pletion: 15 October 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ivosidenib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05907057
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465953-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT06465953)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3.\nStudy: Ivosidenib (IVO) Monoth
 erapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating A
 gent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation\nEs
 timated primary completion: 1 November 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06465953
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04774393-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20271129
DTEND;VALUE=DATE:20271130
SUMMARY:Tibsovo (Ivosidenib): Phase 1/2 readout est. (NCT04774393)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 1/2\, Acute Myeloid Leukemia.\nStu
 dy: Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib 
 or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Le
 ukemia\nEstimated primary completion: 29 November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04774393
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05876754-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT05876754)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3.\nStudy: An Early Access Study o
 f Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic 
 Cholangiocarcinoma\nEstimated primary completion: 1 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ivosidenib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05876754
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392242-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT07392242)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : A Study of the Combination of Ivosidenib\, Azacitidine\, and Venetoclax 
 Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia\nEstima
 ted primary completion: January 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07392242
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06707493-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT06707493)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Ivosidenib as Post-HSCT Maintenance for AML\nEstimated primary completio
 n: 1 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iv
 osidenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06707493
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265545-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Tibsovo (Ivosidenib): Phase na readout est. (NCT06265545)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase na\, Acute Myeloid Leukemia.\nStud
 y: Multicenter\, Platform-type Clinical Study of Refractory/Recurrent Acut
 e Myeloid Leukemia\nEstimated primary completion: 30 January 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ivosidenib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06265545
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06127407-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT06127407)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3.\nStudy: Ivosidenib in Participa
 nts With Locally Advanced or Metastatic Conventional Chondrosarcoma Untrea
 ted or Previously Treated With 1 or 2 Systemic Treatment Regimens\nEstimat
 ed primary completion: 1 February 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06127407
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07131059-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280510
DTEND;VALUE=DATE:20280511
SUMMARY:Tibsovo (Ivosidenib): Phase na readout est. (NCT07131059)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase na\, Acute Myeloid Leukemia.\nStud
 y: MRD-positive AML Clinical Study\nEstimated primary completion: 10 May 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ivosidenib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07131059
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04493164-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT04493164)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid L
 eukemia or High-Risk Myelodysplastic Syndrome\nEstimated primary completio
 n: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivosi
 denib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04493164
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07006688-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Tibsovo (Ivosidenib): Phase 1 readout est. (NCT07006688)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 1.\nStudy: A Study of an IDH1m Inh
 ibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal
  Impairment\nEstimated primary completion: 31 July 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07006688
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07937124-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20281214
DTEND;VALUE=DATE:20281215
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT07937124)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : An All-Oral Combination of Ivosidenib\, Sonrotoclax\, and Chidamide for 
 Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation (ISC)\nEstima
 ted primary completion: 14 December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07937124
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507760-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT07507760)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML 
 Patients\nEstimated primary completion: April 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07507760
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06291987-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Tibsovo (Ivosidenib): Phase 1 readout est. (NCT06291987)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 1.\nStudy: Ivosidenib and Ruxoliti
 nib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Hav
 e an IDH1 Gene Mutation\nEstimated primary completion: May 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06291987
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06717958-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT06717958)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic St
 em Cell Transplantation in Patients With Acute Myeloid Leukemia or High-ri
 sk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutati
 on\nEstimated primary completion: 1 October 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06717958
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05030441-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT05030441)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2.\nStudy: Ivosidenib for Patients
  With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1\
 nEstimated primary completion: 31 January 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05030441
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463768-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT07463768)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib t
 o Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leuke
 mia (AML) and IDH1 Mutation\, in Complete Remission After Intensive Chemot
 herapy.\nEstimated primary completion: September 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07463768
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07260175-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Tibsovo (Ivosidenib): Phase 2 readout est. (NCT07260175)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2.\nStudy: Phase II Study Evaluati
 ng Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH
 1 Cholangiocarcinoma\nEstimated primary completion: December 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ivosidenib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07260175
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03013998-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Tibsovo (Ivosidenib): Phase 2/3 readout est. (NCT03013998)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 2/3\, Acute Myeloid Leukemia.\nStu
 dy: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia\nEstimate
 d primary completion: December 2032. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03013998
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745296-2899@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20330702
DTEND;VALUE=DATE:20330703
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT07745296)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3.\nStudy: Investigating Precision
  Medicine in the Adjuvant Setting in Biliary Tract Cancer\nEstimated prima
 ry completion: 2 July 2033. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ivosidenib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07745296
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
